{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T06:12:50Z","timestamp":1788588770728,"version":"build-2803163510"},"reference-count":48,"publisher":"Elsevier BV","issue":"34","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.vaccine.2016.06.021","type":"journal-article","created":{"date-parts":[[2016,6,12]],"date-time":"2016-06-12T06:20:03Z","timestamp":1465712403000},"page":"4050-4055","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":81,"title":["Rabbits immunized with Epstein-Barr virus gH\/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350"],"prefix":"10.1016","volume":"34","author":[{"given":"Xinle","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouhong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swadhinya","family":"Arjunaraja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L.","family":"Snow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifford M.","family":"Snapper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.06.021_b0005","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s12250-015-3592-5","article-title":"The role of Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma","volume":"30","author":"Tsang","year":"2015","journal-title":"Virol Sin"},{"key":"10.1016\/j.vaccine.2016.06.021_b0010","doi-asserted-by":"crossref","first-page":"107fs7","DOI":"10.1126\/scitranslmed.3002878","article-title":"Epstein-Barr virus: an important vaccine target for cancer prevention","volume":"3","author":"Cohen","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2016.06.021_b0015","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.semcancer.2015.04.006","article-title":"Cross-talk between Epstein-Barr virus and microenvironment in the pathogenesis of lymphomas","volume":"34","author":"Dolcetti","year":"2015","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.vaccine.2016.06.021_b0020","doi-asserted-by":"crossref","first-page":"e1004656","DOI":"10.1371\/journal.ppat.1004656","article-title":"To be or not IIb: a multi-step process for Epstein-Barr virus latency establishment and consequences for B cell tumorigenesis","volume":"11","author":"Price","year":"2015","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2016.06.021_b0025","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1053\/j.seminoncol.2014.12.030","article-title":"Epstein-Barr virus-associated lymphomas","volume":"42","author":"Grywalska","year":"2015","journal-title":"Semin Oncol"},{"key":"10.1016\/j.vaccine.2016.06.021_b0030","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.3390\/v4123420","article-title":"Epstein-Barr virus (EBV)-associated gastric carcinoma","volume":"4","author":"Iizasa","year":"2012","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2016.06.021_b0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1462399404008440","article-title":"Infectious mononucleosis and Epstein-Barr virus","volume":"6","author":"Vetsika","year":"2004","journal-title":"Expert Rev Mol Med"},{"key":"10.1016\/j.vaccine.2016.06.021_b0040","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1146\/annurev-immunol-032414-112326","article-title":"The immunology of Epstein-Barr virus-induced disease","volume":"33","author":"Taylor","year":"2015","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.vaccine.2016.06.021_b0045","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1093\/jnci\/92.18.1522","article-title":"Risk of Hodgkin\u2019s disease and other cancers after infectious mononucleosis","volume":"92","author":"Hjalgrim","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.vaccine.2016.06.021_b0050","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1056\/NEJMoa023141","article-title":"Characteristics of Hodgkin\u2019s lymphoma after infectious mononucleosis","volume":"349","author":"Hjalgrim","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2016.06.021_b0055","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/WCO.0000000000000205","article-title":"Advances in the immunopathogenesis of multiple sclerosis","volume":"28","author":"Yadav","year":"2015","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.vaccine.2016.06.021_b0060","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1177\/1352458513509510","article-title":"Epstein-Barr virus is a necessary causative agent in the pathogenesis of multiple sclerosis: commentary","volume":"19","author":"Hutchinson","year":"2013","journal-title":"Mult Scler"},{"key":"10.1016\/j.vaccine.2016.06.021_b0065","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1634\/theoncologist.11-6-674","article-title":"Post-transplant lymphoproliferative disorders","volume":"11","author":"LaCasce","year":"2006","journal-title":"Oncologist"},{"key":"10.1016\/j.vaccine.2016.06.021_b0070","doi-asserted-by":"crossref","first-page":"7825","DOI":"10.1128\/JVI.00445-07","article-title":"Epstein-Barr virus entry","volume":"81","author":"Hutt-Fletcher","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.06.021_b0075","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.coviro.2013.12.001","article-title":"Epstein Barr virus entry; kissing and conjugation","volume":"4","author":"Shannon-Lowe","year":"2014","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.vaccine.2016.06.021_b0080","doi-asserted-by":"crossref","first-page":"15036","DOI":"10.1073\/pnas.232381299","article-title":"Glycoprotein gp110 of Epstein-Barr virus determines viral tropism and efficiency of infection","volume":"99","author":"Neuhierl","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2016.06.021_b0085","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1074-7613(00)80622-6","article-title":"EBV persistence in memory B cells in vivo","volume":"9","author":"Babcock","year":"1998","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2016.06.021_b0090","doi-asserted-by":"crossref","first-page":"16242","DOI":"10.1073\/pnas.1418974111","article-title":"Epstein-Barr virus replicating in epithelial cells","volume":"111","author":"Hutt-Fletcher","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2016.06.021_b0095","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.semcancer.2012.02.004","article-title":"The biology of EBV infection in human epithelial cells","volume":"22","author":"Tsao","year":"2012","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.vaccine.2016.06.021_b0100","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1084\/jem.176.5.1405","article-title":"Characterization of an Epstein-Barr virus receptor on human epithelial cells","volume":"176","author":"Birkenbach","year":"1992","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2016.06.021_b0105","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1099\/0022-1317-82-10-2373","article-title":"Roles of Epstein-Barr virus glycoproteins gp350 and gp25 in the infection of human epithelial cells","volume":"82","author":"Maruo","year":"2001","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2016.06.021_b0110","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1128\/JVI.73.3.2115-2125.1999","article-title":"CD21-dependent infection of an epithelial cell line, 293, by Epstein-Barr virus","volume":"73","author":"Fingeroth","year":"1999","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.06.021_b0115","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1128\/JVI.72.5.4371-4378.1998","article-title":"Cell-to-cell contact as an efficient mode of Epstein-Barr virus infection of diverse human epithelial cells","volume":"72","author":"Imai","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.06.021_b0120","doi-asserted-by":"crossref","first-page":"e1001338","DOI":"10.1371\/journal.ppat.1001338","article-title":"Epstein-Barr virus infection of polarized epithelial cells via the basolateral surface by memory B cell-mediated transfer infection","volume":"7","author":"Shannon-Lowe","year":"2011","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2016.06.021_b0125","doi-asserted-by":"crossref","first-page":"16544","DOI":"10.1073\/pnas.1400818111","article-title":"Efficient replication of Epstein-Barr virus in stratified epithelium in vitro","volume":"111","author":"Temple","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2016.06.021_b0130","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/356347a0","article-title":"Epstein-Barr virus infection and replication in a human epithelial cell system","volume":"356","author":"Li","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2016.06.021_b0135","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1600-0714.2008.00681.x","article-title":"Laser-capture microdissection of oropharyngeal epithelium indicates restriction of Epstein-Barr virus receptor\/CD21 mRNA to tonsil epithelial cells","volume":"37","author":"Jiang","year":"2008","journal-title":"J Oral Pathol Med"},{"key":"10.1016\/j.vaccine.2016.06.021_b0140","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1038\/cti.2014.27","article-title":"Epstein-barr virus vaccines","volume":"4","author":"Cohen","year":"2015","journal-title":"Clin Trans Immunol"},{"key":"10.1016\/j.vaccine.2016.06.021_b0145","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1086\/523813","article-title":"Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults","volume":"196","author":"Sokal","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.06.021_b0150","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1016\/j.vaccine.2007.04.008","article-title":"Phase I\/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults","volume":"25","author":"Moutschen","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.06.021_b0155","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1097\/TP.0b013e3181b9d918","article-title":"A phase I trial of Epstein-Barr virus gp350 vaccine for children with chronic kidney disease awaiting transplantation","volume":"88","author":"Rees","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.vaccine.2016.06.021_b0160","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/eji.200425749","article-title":"High epitope density in a single protein molecule significantly enhances antigenicity as well as immunogenicity: a novel strategy for modern vaccine development and a preliminary investigation about B cell discrimination of monomeric proteins","volume":"35","author":"Liu","year":"2005","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2016.06.021_b0165","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1016\/j.vaccine.2008.03.078","article-title":"Adjuvant potential of aggregate-forming polyglutamine domains","volume":"26","author":"Ilyinskii","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.06.021_b0170","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1089\/jir.2010.0086","article-title":"On the role of aggregates in the immunogenicity of recombinant human interferon beta in patients with multiple sclerosis","volume":"30","author":"van Beers","year":"2010","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.vaccine.2016.06.021_b0175","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.1002\/1521-4141(200211)32:11<3305::AID-IMMU3305>3.0.CO;2-J","article-title":"Regulation of IgG antibody responses by epitope density and CD21-mediated costimulation","volume":"32","author":"Jegerlehner","year":"2002","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2016.06.021_b0180","doi-asserted-by":"crossref","first-page":"E501","DOI":"10.1208\/aapsj080359","article-title":"Effects of protein aggregates: an immunologic perspective","volume":"8","author":"Rosenberg","year":"2006","journal-title":"AAPS J"},{"key":"10.1016\/j.vaccine.2016.06.021_b0185","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/0264-410X(94)90237-2","article-title":"Enhanced immunogenicity of protein-dextran conjugates: I. Rapid stimulation of enhanced antibody responses to poorly immunogenic molecules","volume":"12","author":"Lees","year":"1994","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.06.021_b0190","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1016\/j.vaccine.2013.04.071","article-title":"A novel tetrameric gp350 1\u2013470 as a potential Epstein-Barr virus vaccine","volume":"31","author":"Cui","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.06.021_b0195","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.jmb.2004.02.020","article-title":"Very fast folding and association of a trimerization domain from bacteriophage T4 fibritin","volume":"337","author":"Guthe","year":"2004","journal-title":"J Mol Biol"},{"key":"10.1016\/j.vaccine.2016.06.021_b0200","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2174\/1570163043334938","article-title":"Applications of multi-angle laser light-scattering detection in the analysis of peptides and proteins","volume":"1","author":"Oliva","year":"2004","journal-title":"Curr Drug Discov Technol"},{"key":"10.1016\/j.vaccine.2016.06.021_b0205","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1073\/pnas.0810530106","article-title":"Structure of a trimeric variant of the Epstein-Barr virus glycoprotein B","volume":"106","author":"Backovic","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2016.06.021_b0210","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.virol.2009.06.013","article-title":"Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assay","volume":"391","author":"Sashihara","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2016.06.021_b0215","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/0092-8674(89)90240-7","article-title":"Identification of an epitope in the major envelope protein of Epstein-Barr virus that mediates viral binding to the B lymphocyte EBV receptor (CR2)","volume":"56","author":"Nemerow","year":"1989","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2016.06.021_b0220","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/0042-6822(84)90102-8","article-title":"Early events in the infection of human B lymphocytes by Epstein-Barr virus: the internalization process","volume":"132","author":"Nemerow","year":"1984","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2016.06.021_b0225","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.cell.2015.07.043","article-title":"Rational design of an Epstein-Barr virus vaccine targeting the receptor-binding site","volume":"162","author":"Kanekiyo","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2016.06.021_b0230","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa0804749","article-title":"Vaccine prevention of maternal cytomegalovirus infection","volume":"360","author":"Pass","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2016.06.021_b0235","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0140-6736(11)60136-0","article-title":"Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial","volume":"377","author":"Griffiths","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2016.06.021_b0240","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1128\/JVI.43.2.730-736.1982","article-title":"Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo","volume":"43","author":"Thorley-Lawson","year":"1982","journal-title":"J Virol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16304340?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16304340?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T00:29:12Z","timestamp":1600734552000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16304340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":48,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0264410X16304340"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.06.021","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rabbits immunized with Epstein-Barr virus gH\/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.06.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}